EFFICIENT SCALE-UP OF IPS CELLS FOR AUTOLOGOUS CELL THERAPY WORKFLOW
高效扩大 IPS 细胞的自体细胞治疗工作流程
基本信息
- 批准号:10822298
- 负责人:
- 金额:$ 27.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-15 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AutologousBenchmarkingBiologicalBioreactorsCell CountCell Culture TechniquesCell DeathCell TherapyCellsClinicalComplexCyclic GMPDevelopmentDevicesDoseEngineeringFeedbackFlow CytometryFutureGenerationsGerm CellsGoalsHarvestHealthcare SystemsHumanIn VitroKaryotype determination procedureLaboratoriesLinkMaintenanceManualsMarketingMeasurementMedicineModelingNutrientOutcomeOutputParacrine CommunicationPatientsPerfusionPharmaceutical PreparationsPhasePhysiologicalPopulationPositioning AttributeProcessProviderQuality ControlResearchSamplingSerum-Free Culture MediaSmall Business Innovation Research GrantStructureSuspensionsTechniquesTechnologyTimeTissue Culture TechniquesTissuesTrainingTranslatingTranslationsUniversitiesVariantWorkcell typeclinical predictorsclinically relevantcommercial applicationcostcost efficientdesignexperimental studyhealth care economicsimprovedin silicoinduced pluripotent stem cellinnovationmanufacturing processpluripotencyprecision medicinepreservationprototypescale upshear stressstemstem cell expansionsuccessthree dimensional cell culturetimelineuser-friendly
项目摘要
Project Summary/Abstract
Cell expansion is a critical step for cell therapy, hindered by expensive and complex bioreactor requirements to
yield sufficient cell numbers for adequate dosing and requiring expensive regents to enhance functionality for
increased clinical success. To support the use of patient cells within the cell therapy workflow, there is a need
for bioreactors designed for expanding patient cells from an initial iPS clonal population to clinically relevant cell
doses. These reactors must also be suitable for cGMP processes and economically efficient to enable their utility
within the healthcare system. Overall, there is a need for clinically relevant cell expansion technologies that are
robust and efficient enough to enable the realization of autologous cell therapy workflows as a viable treatment
option for all. Thus, the unmet need we will address is providing a bioreactor-based workflow for the efficient
translation of patient cells into high-quality iPS cell based therapeutics in a patient-specific manner – benefiting
drug developers, patients, clinicians, and the healthcare economy. Our universal approach to cell expansion
(OnXpansion) uses a defined serum-free media and relies on controlled aggregation for enhanced paracrine
signaling and cell-cell contact, enhanced nutrient delivery via low-shear perfusion, and organotypic tissue niches
to generate thousands of identical spheroid tissues that can be further scaled to yield adequate cell numbers
for cell therapy at both reduced costs and manual labor. Our approach to translating this technology center
around de-risking its utility for precision medicine and increasing its suitability and handling within the intended
customer workflows. Our bioreactor products are efficient (cost, time, labor), easy to use, automated, reliable,
robust, physiologically relevant, and clinically predictive. The large unmet need and low barrier for entry positions
Link favorably against competitors. Overall, Link’s products are designed to enable a reliable and robust
precision medicine workflow that is efficient and of high biological fidelity, thereby enabling a future where cell
therapy is more accessible to the patient, via decreased costs, and the provider, via simplified workflows.
项目总结/摘要
细胞扩增是细胞治疗的关键步骤,受到昂贵且复杂的生物反应器要求的阻碍,
产生足够的细胞数量用于足够的剂量,并且需要昂贵的试剂来增强功能,
提高临床成功率。为了支持在细胞治疗工作流程中使用患者细胞,需要
对于设计用于将患者细胞从初始iPS克隆群体扩增为临床相关细胞的生物反应器
剂量这些反应器还必须适用于cGMP工艺,并且经济有效,以使其能够使用
在医疗系统内。总的来说,需要临床相关的细胞扩增技术,
足够强大和有效,能够实现自体细胞治疗工作流程作为一种可行的治疗
所有人的选择。因此,我们将解决的未满足的需求是提供基于生物反应器的工作流程,以实现高效的生物降解。
以患者特异性的方式将患者细胞转化为高质量的基于iPS细胞的治疗剂,
药物开发人员、患者、临床医生和医疗保健经济。我们的通用细胞扩增方法
(OnXpansion)使用确定的无血清培养基,并依赖于受控的聚集以增强旁分泌
信号传导和细胞-细胞接触,通过低剪切灌注增强营养输送,以及器官型组织小生境
以产生数千个相同的球状体组织,这些球状体组织可以进一步缩放以产生足够的细胞数量
用于细胞治疗,既降低了成本又减少了手工劳动。我们将这个技术中心
围绕降低其用于精准医疗的风险,并在预期范围内增加其适用性和处理
客户工作流程。我们的生物反应器产品高效(成本,时间,劳动力),易于使用,自动化,可靠,
稳健、生理相关和临床预测。大量未满足的需求和进入职位的低门槛
与竞争对手建立有利的联系。总体而言,Link的产品旨在实现可靠和强大的
精确的医学工作流程是有效的和高度的生物保真度,从而使未来的细胞,
通过降低成本,患者更容易获得治疗,通过简化工作流程,提供者更容易获得治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kacey Ronaldson其他文献
Kacey Ronaldson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kacey Ronaldson', 18)}}的其他基金
EFFICIENT DIFFERENTIATION, SCALE-UP, AND MATURATION OF IPS DERIVED CARDIOMYOCYTES
IPS 来源的心肌细胞的有效分化、放大和成熟
- 批准号:
10761485 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
CELL EXPANSION BIOREACTORS FOR ASSAY-READY IMMUNOCOMPETENT PATIENT MODELS
用于检测准备的免疫功能正常患者模型的细胞扩增生物反应器
- 批准号:
10688981 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
相似国自然基金
企业绩效评价的DEA-Benchmarking方法及动态博弈研究
- 批准号:70571028
- 批准年份:2005
- 资助金额:16.5 万元
- 项目类别:面上项目
相似海外基金
An innovative EDI data, insights & peer benchmarking platform enabling global business leaders to build data-led EDI strategies, plans and budgets.
创新的 EDI 数据、见解
- 批准号:
10100319 - 财政年份:2024
- 资助金额:
$ 27.56万 - 项目类别:
Collaborative R&D
BioSynth Trust: Developing understanding and confidence in flow cytometry benchmarking synthetic datasets to improve clinical and cell therapy diagnos
BioSynth Trust:发展对流式细胞仪基准合成数据集的理解和信心,以改善临床和细胞治疗诊断
- 批准号:
2796588 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
Studentship
Collaborative Research: SHF: Medium: A Comprehensive Modeling Framework for Cross-Layer Benchmarking of In-Memory Computing Fabrics: From Devices to Applications
协作研究:SHF:Medium:内存计算结构跨层基准测试的综合建模框架:从设备到应用程序
- 批准号:
2347024 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
Standard Grant
Elements: CausalBench: A Cyberinfrastructure for Causal-Learning Benchmarking for Efficacy, Reproducibility, and Scientific Collaboration
要素:CausalBench:用于因果学习基准测试的网络基础设施,以实现有效性、可重复性和科学协作
- 批准号:
2311716 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
Standard Grant
Benchmarking collisional rates and hot electron transport in high-intensity laser-matter interaction
高强度激光-物质相互作用中碰撞率和热电子传输的基准测试
- 批准号:
2892813 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
Studentship
Collaborative Research: BeeHive: A Cross-Problem Benchmarking Framework for Network Biology
合作研究:BeeHive:网络生物学的跨问题基准框架
- 批准号:
2233969 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
Continuing Grant
FET: Medium: Quantum Algorithms, Complexity, Testing and Benchmarking
FET:中:量子算法、复杂性、测试和基准测试
- 批准号:
2311733 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
Continuing Grant
Establishing and benchmarking advanced methods to comprehensively characterize somatic genome variation in single human cells
建立先进方法并对其进行基准测试,以全面表征单个人类细胞的体细胞基因组变异
- 批准号:
10662975 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
Collaborative Research: BeeHive: A Cross-Problem Benchmarking Framework for Network Biology
合作研究:BeeHive:网络生物学的跨问题基准框架
- 批准号:
2233968 - 财政年份:2023
- 资助金额:
$ 27.56万 - 项目类别:
Continuing Grant